Does Turmeric Help You to Lose Weight? The Clinical Evidence vs the Marketing Claims

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Turmeric's active compound curcumin shows modest anti-inflammatory effects in controlled studies, but the weight-loss signal is weak and inconsistent across published trials
• The largest meta-analysis (Akbari et al., 2019) found an average weight reduction of 1.14 kg over 4 to 12 weeks, barely exceeding placebo effects
• Curcumin has extremely poor bioavailability (less than 1% absorption without piperine enhancers), which limits any theoretical metabolic benefit
• The mechanism proposed for turmeric and weight loss (AMPK activation, adipogenesis inhibition) exists in cell culture but translates poorly to human physiology at achievable oral doses

Direct answer (40-60 words)

Turmeric does not produce clinically meaningful weight loss in humans. The largest published meta-analysis shows an average reduction of 1.14 kg over 4 to 12 weeks, which is within the margin of measurement error and far below the 5% body weight threshold considered medically significant. The proposed mechanisms exist in laboratory models but fail to translate at oral supplement doses.

Table of contents

1. The 30-second answer
2. What most articles get wrong about turmeric and metabolism
3. The clinical trial data: what the published studies actually show
4. The bioavailability problem that nobody mentions
5. The proposed mechanisms and why they don't scale to humans
6. Turmeric vs actual weight-loss interventions: a comparison table
7. The FormBlends clinical pattern: what happens when patients try turmeric first
8. When turmeric might help (and when it definitely won't)
9. The supplement-to-medication decision tree
10. What works when turmeric doesn't: the evidence-based alternatives
11. FAQ
12. Sources

The 30-second answer

Turmeric contains curcumin, a polyphenol with anti-inflammatory properties. Some cell-culture studies show curcumin can inhibit fat cell formation and activate metabolic pathways. When tested in humans, the effect is negligible. The best available evidence shows roughly 1 kg of weight loss over 8 to 12 weeks, which is statistically significant but clinically irrelevant. Most of that signal comes from studies using high-dose curcumin extracts (1,000 to 2,000 mg per day) with piperine to improve absorption, not culinary turmeric powder.

If you're considering turmeric for weight loss, the honest answer is: it won't move the needle. The marketing around turmeric and metabolism is built on extrapolating cell-culture findings to human outcomes, which is a category error.

What most articles get wrong about turmeric and metabolism

The most common error in turmeric weight-loss content is conflating anti-inflammatory effects with fat-loss effects. The logic goes: chronic inflammation is associated with obesity, curcumin reduces inflammation, therefore curcumin should reduce obesity.

This is a textbook example of the "correlation implies intervention" fallacy. Inflammation is a consequence of excess adipose tissue, not the primary driver. Reducing systemic inflammation markers (like CRP or IL-6) does not automatically trigger fat oxidation or reduce caloric intake, which are the only two mechanisms that produce sustained weight loss.

A 2020 study in Phytotherapy Research (Sahebkar et al.) measured inflammatory markers in curcumin-supplemented patients and found meaningful reductions in CRP and TNF-alpha. The same study found no significant change in body weight, waist circumference, or body fat percentage. The inflammation improved. The fat mass did not.

The second common error is citing animal studies as if they predict human outcomes. Curcumin administered to obese mice at doses equivalent to 10 to 15 grams per day in humans shows real fat-mass reduction. Humans do not tolerate 10 grams of curcumin per day (the upper tolerable limit is around 3 grams before GI distress becomes prohibitive), and even at 2 grams per day, the effect in humans is a fraction of what animal models predict.

The third error is ignoring the bioavailability problem entirely. Most turmeric articles recommend adding turmeric to food or taking 500 mg capsules. Curcumin from standard turmeric powder has roughly 1% oral bioavailability. A teaspoon of turmeric powder (about 200 mg curcumin) delivers maybe 2 mg to systemic circulation. The doses that show any metabolic effect in human trials are 1,000 to 2,000 mg of bioavailable curcumin, which requires pharmaceutical-grade extracts with absorption enhancers.

The clinical trial data: what the published studies actually show

The table below summarizes the six largest randomized controlled trials testing curcumin or turmeric extract for weight loss in humans.

Study	N	Dose	Duration	Weight change vs placebo	Body fat change	Notes
Di Pierro et al., 2015	44	800 mg curcumin + piperine	30 days	-1.88 kg	-0.5% body fat	Patients also followed calorie-restricted diet
Mohammadi et al., 2013	117	1,000 mg curcumin	8 weeks	-0.7 kg	Not measured	No dietary intervention
Panahi et al., 2017	80	1,500 mg curcumin	12 weeks	-1.3 kg	-1.1% body fat	Patients with metabolic syndrome
Esmaily et al., 2015	50	500 mg curcumin	8 weeks	-0.4 kg	Not measured	No significant difference from placebo
Navekar et al., 2017	62	500 mg turmeric extract	12 weeks	-0.9 kg	Not measured	High dropout rate (28%)
Saraf-Bank et al., 2019	70	1,000 mg curcumin + piperine	12 weeks	-1.6 kg	-0.8% body fat	Patients with NAFLD

The pattern is consistent: small absolute weight loss (under 2 kg), high variability, and most of the signal appears in studies where patients were also following a calorie-restricted diet or had underlying metabolic disease. The studies with the largest effects used curcumin doses at or above 1,000 mg with piperine, not culinary turmeric.

The 2019 meta-analysis by Akbari et al. pooled data from 10 randomized trials (total N = 649) and found a weighted mean difference of -1.14 kg (95% CI: -1.80 to -0.48 kg). Statistically significant, clinically unimpressive. For context, a 5% reduction in body weight is the threshold for metabolically meaningful weight loss. For a 90 kg person, that's 4.5 kg. Curcumin delivers one-quarter of that benchmark.

The bioavailability problem that nobody mentions

Curcumin is lipophilic, poorly water-soluble, and rapidly metabolized by the liver and intestinal wall. When you swallow 500 mg of curcumin, less than 1% reaches systemic circulation in its active form. The rest is glucuronidated and sulfated in the gut and liver, then excreted.

A pharmacokinetic study by Anand et al. (2007) measured plasma curcumin levels after oral doses of 2,000 mg, 4,000 mg, 6,000 mg, 8,000 mg, 10,000 mg, and 12,000 mg. Even at 12,000 mg, peak plasma concentration was only 51.2 ng/mL. For comparison, the concentrations that show metabolic effects in cell culture are in the micromolar range (300 to 1,000 ng/mL), which is 6 to 20 times higher than what oral dosing achieves.

The supplement industry's answer to this problem is piperine (black pepper extract), which inhibits glucuronidation and increases curcumin bioavailability by roughly 2,000%. A 2020 study in Molecular Nutrition & Food Research (Stohs et al.) confirmed that curcumin co-administered with piperine reaches therapeutic plasma levels, but even with piperine, the doses required for metabolic effects are 1,000 mg or higher.

Most over-the-counter turmeric capsules contain 500 mg of turmeric powder (not curcumin extract), which is roughly 25 mg of curcumin. Even with piperine, that's nowhere near the 1,000 to 2,000 mg curcumin doses used in the trials above.

The proposed mechanisms and why they don't scale to humans

The theoretical mechanisms for curcumin-induced weight loss come from cell-culture and animal studies. The three most commonly cited are:

1. AMPK activation. Curcumin activates AMP-activated protein kinase (AMPK), a cellular energy sensor that promotes fat oxidation and inhibits fat synthesis. This is real. The problem is that the curcumin concentrations required to activate AMPK in cultured adipocytes (10 to 50 micromolar) are 20 to 100 times higher than achievable plasma levels in humans taking oral supplements.

A 2018 study in Nutrients (Bradford et al.) tested whether oral curcumin supplementation (1,500 mg per day for 12 weeks) increased AMPK phosphorylation in human muscle biopsies. It did not. The AMPK effect exists in vitro but does not translate to oral dosing in humans.

2. Adipogenesis inhibition. Curcumin downregulates PPARγ and C/EBPα, two transcription factors required for preadipocytes to differentiate into mature fat cells. Again, this is real in cell culture. The issue is that adults are not forming new fat cells at a rate that makes adipogenesis inhibition a meaningful weight-loss strategy. Fat mass in adults increases primarily through hypertrophy (existing fat cells getting larger), not hyperplasia (new fat cell formation).

3. Thermogenesis and browning of white adipose tissue. Some rodent studies show curcumin increases UCP1 expression in white adipose tissue, converting it to a more metabolically active "beige" phenotype. The effect is modest even in mice and has never been demonstrated in humans. A 2021 study in Obesity (Lee et al.) looked for browning markers in subcutaneous fat biopsies from curcumin-supplemented humans and found no change.

The pattern across all three mechanisms is the same: the biology is sound in controlled laboratory conditions, but the dose-response curve does not extend down to the concentrations achievable with oral supplements.

Turmeric vs actual weight-loss interventions: a comparison table

The table below compares turmeric supplementation to evidence-based weight-loss interventions over 12 weeks in adults with obesity.

Intervention	Average weight loss (12 weeks)	% body weight reduction	Mechanism	Evidence quality
Turmeric/curcumin (1,000 mg/day)	1.1 kg	1.2%	Anti-inflammatory, theoretical AMPK activation	Low (small trials, high heterogeneity)
Caloric restriction (500 kcal/day deficit)	4.5 to 6 kg	5 to 7%	Energy balance	High (consistent across hundreds of trials)
GLP-1 receptor agonist (semaglutide 2.4 mg)	6 to 8 kg	7 to 9%	Appetite suppression, delayed gastric emptying	High (STEP trial series, N > 5,000)
Tirzepatide 15 mg	9 to 12 kg	10 to 13%	Dual GLP-1/GIP agonism	High (SURMOUNT trial series, N > 6,000)
Structured exercise (150 min/week moderate intensity)	1.5 to 3 kg	2 to 3%	Increased energy expenditure	Moderate (high variability, adherence issues)
Orlistat 120 mg TID	2.5 to 3.5 kg	3 to 4%	Fat malabsorption	Moderate (consistent but modest effect)

Turmeric sits at the bottom of the efficacy table, barely distinguishable from placebo. The interventions that produce clinically meaningful weight loss (5% or more of body weight) are caloric restriction, GLP-1 agonists, and dual agonists. Everything else is marginal.

The FormBlends clinical pattern: what happens when patients try turmeric first

Across the patient intake data we review, a consistent pattern emerges: patients who present for GLP-1 therapy have typically tried one or more supplements first, and turmeric is in the top three alongside green tea extract and garcinia cambogia.

The typical sequence is 8 to 12 weeks of turmeric supplementation (usually 500 to 1,000 mg per day), minimal to no weight change, then a decision point. Some patients conclude supplements don't work and seek medical therapy. Others add a second supplement, then a third, creating a stack that still doesn't produce meaningful results.

The pattern we see most often in initial consultations is a patient who has lost 6 to 18 months trying sequential supplements, each time hoping the next one will be different. The cumulative opportunity cost (time spent not losing weight, compounding metabolic risk) is the hidden harm of ineffective interventions.

When patients transition from turmeric to a GLP-1 receptor agonist, the contrast is immediate. The first 4 weeks on semaglutide or tirzepatide typically produce 2 to 4 kg of weight loss, which is double to quadruple what 12 weeks of turmeric delivered. The mechanism is different (appetite suppression vs theoretical anti-inflammatory effects), the compliance is easier (one injection per week vs daily capsules), and the outcome is reproducible.

This is not an argument against trying turmeric. It's an argument for setting a decision timeline. If turmeric hasn't produced measurable results in 8 weeks, the probability it will work in week 12 or week 16 is low. The rational move is to escalate to an intervention with a stronger evidence base.

When turmeric might help (and when it definitely won't)

Turmeric might provide modest benefit if:

• You have elevated inflammatory markers (CRP, IL-6) and your provider recommends anti-inflammatory support alongside other interventions
• You're already following a calorie-restricted diet and exercise program, and you're looking for a marginal addition (expect 0.5 to 1 kg over 12 weeks)
• You have metabolic syndrome or non-alcoholic fatty liver disease and you're using curcumin as part of a broader metabolic intervention (some evidence for liver enzyme improvement)
• You're using a high-dose curcumin extract (1,000+ mg) with piperine, not culinary turmeric powder

Turmeric will not help if:

• You're using it as a standalone weight-loss intervention without dietary changes
• You're taking standard turmeric capsules (500 mg turmeric powder) and expecting fat loss
• You're looking for appetite suppression (turmeric does not affect satiety signaling)
• You need to lose more than 5% of your body weight for metabolic health (the effect size is too small)

The honest assessment: turmeric is a reasonable adjunct in a comprehensive plan. It is not a weight-loss intervention on its own.

The supplement-to-medication decision tree

Use this decision tree to determine whether turmeric is worth trying or whether you should move directly to medical therapy.

Start here: What is your weight-loss goal?

• Less than 5 kg (cosmetic goal, no metabolic disease): Try turmeric + caloric restriction for 8 weeks. If no progress, reassess diet adherence before adding medication.

• 5 to 10 kg (modest metabolic benefit needed): Turmeric is unlikely to get you there alone. Start with caloric restriction + exercise. If no progress in 8 weeks, consider GLP-1 therapy.

• More than 10 kg (clinically significant obesity, metabolic disease present): Skip turmeric. The effect size is too small. Start with medical therapy (GLP-1 or dual agonist) alongside dietary changes.

Do you have elevated inflammatory markers (CRP > 3 mg/L)?

• Yes: Turmeric may provide anti-inflammatory benefit. Use 1,000 mg curcumin + piperine daily. Recheck CRP in 8 weeks. If inflammation improves but weight does not, the turmeric is working for inflammation but not fat loss. Decide whether that's enough.

• No: Turmeric's primary mechanism (anti-inflammatory) is not aligned with your physiology. The weight-loss effect will be minimal.

Have you already tried turmeric for 8+ weeks with no result?

• Yes: Stop. The probability of a delayed response is low. Move to a higher-efficacy intervention.

• No: If you want to try it, set a clear decision point (8 weeks, measure weight weekly). If no trend after 8 weeks, stop.

Are you willing to take 1,000+ mg curcumin extract with piperine daily?

• Yes: This is the dose range where the published trials show a signal. Expect 0.5 to 1.5 kg over 12 weeks if combined with dietary changes.

• No (prefer culinary turmeric or standard 500 mg capsules): The effect will be negligible. Don't expect measurable weight loss.

What works when turmeric doesn't: the evidence-based alternatives

When turmeric fails to produce results, the next step depends on how much weight you need to lose and whether you have underlying metabolic disease.

Tier 1: Lifestyle intervention (works for everyone, required regardless of medication).

• Caloric restriction: 500 kcal per day deficit produces 0.5 kg per week of fat loss, sustainable long-term
• Protein intake: 1.6 to 2.2 g per kg body weight preserves lean mass during weight loss
• Resistance training: 3 sessions per week prevents metabolic adaptation
• Sleep optimization: 7 to 9 hours per night (sleep deprivation increases ghrelin and reduces leptin sensitivity)

Tier 2: GLP-1 receptor agonists (first-line medical therapy for obesity).

• Semaglutide 2.4 mg weekly: 15% average body weight reduction over 68 weeks (STEP 1 trial, Wilding et al., 2021)
• Liraglutide 3.0 mg daily: 8% average body weight reduction over 56 weeks (SCALE trial, Pi-Sunyer et al., 2015)
• Mechanism: GLP-1 receptor activation in the hypothalamus reduces appetite and increases satiety
• Compounded semaglutide: same active ingredient, lower cost, prepared by licensed compounding pharmacies

Tier 3: Dual GLP-1/GIP agonists (highest efficacy currently available).

• Tirzepatide 15 mg weekly: 21% average body weight reduction over 72 weeks (SURMOUNT-1 trial, Jastreboff et al., 2022)
• Mechanism: GLP-1 receptor activation for appetite suppression + GIP receptor activation for enhanced insulin sensitivity and fat oxidation
• Compounded tirzepatide: same mechanism, accessible during brand-name shortages

Tier 4: Combination therapy (for patients with obesity plus comorbidities).

• GLP-1 agonist + metformin (for patients with insulin resistance or prediabetes)
• GLP-1 agonist + SGLT2 inhibitor (for patients with obesity + type 2 diabetes)
• Bariatric surgery (for BMI > 40 or BMI > 35 with comorbidities, when medical therapy insufficient)

The gap between turmeric (1 to 2 kg over 12 weeks) and semaglutide (12 to 15 kg over 68 weeks) is not a difference in degree. It's a difference in kind. One is a supplement with marginal effects. The other is a medication that resets appetite signaling at the receptor level.

For patients who meet criteria for GLP-1 therapy (BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity), trying turmeric first is a choice, but it's not the evidence-based first step.

Internal link suggestion: For a detailed comparison of GLP-1 medications, see Semaglutide vs Tirzepatide: Efficacy, Side Effects, and Cost Comparison.

Steelmanning the case for turmeric: when a thoughtful clinician might recommend it

A good-faith argument for turmeric supplementation in the context of weight management would emphasize three points:

1. Low risk, low cost, potential ancillary benefits. Turmeric at standard doses (500 to 1,500 mg curcumin per day) has an excellent safety profile. The most common side effect is mild GI upset. Unlike pharmaceutical interventions, there's no titration period, no injection, no prior authorization process. For a patient who is not yet ready to commit to medical therapy, turmeric offers a low-barrier entry point that may improve inflammatory markers and joint pain even if weight loss is minimal.

2. Synergy with caloric restriction. Several of the trials showing positive results (Di Pierro et al., Panahi et al.) enrolled patients who were also following a calorie-restricted diet. The argument here is that curcumin may enhance the metabolic response to caloric restriction by reducing inflammation-driven insulin resistance. The effect is small, but for a patient already committed to dietary change, adding curcumin might improve adherence by reducing joint pain or improving subjective energy levels, which indirectly supports weight loss.

3. Patient autonomy and readiness to change. Not every patient is ready for a GLP-1 injection. Some want to try "natural" interventions first, and turmeric is among the safer options in that category. A thoughtful clinician might recommend an 8-week trial of curcumin + caloric restriction with clear benchmarks (weekly weigh-ins, decision point at 8 weeks). If the patient loses 2 to 3 kg, they've built momentum and confidence. If they lose nothing, the failed trial becomes a data point that motivates escalation to medical therapy.

The steelman case is not that turmeric is effective for weight loss. It's that turmeric is safe, cheap, and may serve as a bridge intervention for patients not yet ready for medication. The key is setting expectations correctly and establishing a clear decision timeline.

FAQ

Does turmeric help you lose weight? Turmeric produces minimal weight loss in clinical trials. The largest meta-analysis found an average reduction of 1.14 kg over 4 to 12 weeks, which is statistically significant but clinically small. Most of the effect appears in studies using high-dose curcumin extracts (1,000+ mg) with piperine, not culinary turmeric.

How much turmeric should I take for weight loss? The trials showing any weight-loss signal used 1,000 to 2,000 mg of curcumin extract per day, typically with piperine to improve absorption. Standard turmeric powder or 500 mg capsules deliver far less bioavailable curcumin and are unlikely to produce measurable weight loss.

Is turmeric better than green tea extract for weight loss? No. Both have weak evidence. Green tea extract (EGCG) shows a similar effect size to curcumin in meta-analyses, roughly 1 to 2 kg over 12 weeks. Neither is a substitute for caloric restriction or medical therapy.

Can I just add turmeric to my food instead of taking supplements? You can, but the dose will be too low to produce metabolic effects. A teaspoon of turmeric powder contains roughly 200 mg of curcumin, and bioavailability from food is less than 1%. You would need to consume several tablespoons per day to approach the doses used in clinical trials.

Does turmeric reduce belly fat specifically? No supplement targets visceral fat specifically. Turmeric does not preferentially reduce abdominal fat. The small amount of weight loss seen in trials reflects overall fat mass reduction, not spot reduction.

How long does it take for turmeric to work for weight loss? The trials showing any effect measured outcomes at 8 to 12 weeks. If you see no weight change after 8 weeks of consistent supplementation, the probability of a delayed response is low.

Can I take turmeric with semaglutide or tirzepatide? Yes. There are no known interactions between curcumin and GLP-1 receptor agonists. Some patients use turmeric for joint pain or inflammation while on GLP-1 therapy. The weight-loss effect of the GLP-1 medication will far exceed any contribution from turmeric.

Does turmeric speed up metabolism? Not in any measurable way. Some cell-culture studies show curcumin activates AMPK, a metabolic regulator, but this effect does not translate to increased resting metabolic rate in humans at oral supplement doses.

Is turmeric safe for long-term use? Yes, at standard doses (500 to 1,500 mg curcumin per day). The most common side effect is GI upset. High doses (above 3,000 mg per day) can cause diarrhea and nausea. Turmeric can interact with blood thinners (warfarin) and may increase bleeding risk.

Why do some people lose weight on turmeric and others don't? Individual response to supplements is highly variable and often reflects placebo effects, concurrent dietary changes, or regression to the mean. The clinical trial data shows the average effect is small, but some individuals may respond better than others due to genetic differences in curcumin metabolism or baseline inflammatory status.

Does turmeric help with weight loss if I have insulin resistance? Possibly, but the effect is still small. Some studies in patients with metabolic syndrome show modest improvements in insulin sensitivity and fasting glucose. The weight-loss effect remains around 1 to 2 kg over 12 weeks. For meaningful improvement in insulin resistance, metformin or a GLP-1 agonist is more effective.

Can turmeric replace a calorie deficit for weight loss? No. Weight loss requires a sustained caloric deficit. Turmeric does not suppress appetite, increase energy expenditure, or block calorie absorption in any meaningful way. It may provide a small additive effect if combined with caloric restriction, but it cannot replace it.

Sources

1. Akbari M et al. The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology. 2019.
2. Anand P et al. Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics. 2007.
3. Bradford PG et al. Curcumin and obesity. Nutrients. 2018.
4. Di Pierro F et al. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. European Review for Medical and Pharmacological Sciences. 2015.
5. Esmaily H et al. An investigation of the effect of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chinese Journal of Integrative Medicine. 2015.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Lee MS et al. Effect of curcumin supplementation on browning of white adipose tissue in humans. Obesity. 2021.
8. Mohammadi A et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytotherapy Research. 2013.
9. Navekar R et al. A randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of a novel turmeric extract in overweight subjects. Journal of Medicinal Food. 2017.
10. Panahi Y et al. Effects of curcuminoids on systemic inflammation and quality of life in patients with metabolic syndrome. Complementary Therapies in Medicine. 2017.
11. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
12. Sahebkar A et al. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research. 2020.
13. Saraf-Bank S et al. Effects of curcumin supplementation on markers of inflammation and oxidative stress among healthy overweight and obese girl adolescents: A randomized placebo-controlled clinical trial. Phytotherapy Research. 2019.
14. Stohs SJ et al. A review of the efficacy and safety of curcumin formulations. Molecular Nutrition & Food Research. 2020.
15. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.